A phase I study to evaluate the safety, tolerability, and pharmacokinetics of HEC113995PA·H2O, a novel dual-acting serotonergic antidepressant, in healthy subjects
HEC113995PA·H<sub>2</sub>O was safe and generally well-tolerated in healthy subjects. Based on the pharmacokinetic and safety data mentioned above, we expect that postprandial administration will favorably increase drug concentrations in the body and reduce gastrointestinal adverse events.
Authors
- Haiquan Qin (ORCID: https://orcid.org/0000-0001-9977-0889)
- Yulei Zhuang
- Zhangma Huang
- Jingying Jia
- Li Deng (ORCID: https://orcid.org/0009-0004-5690-2078)
- Qichen Ding (ORCID: https://orcid.org/0000-0001-6496-9521)
- Chuanfei Jin (ORCID: https://orcid.org/0000-0002-0024-9530)
- Xue Li (ORCID: https://orcid.org/0000-0003-4988-4495)
- Qian Chen (ORCID: https://orcid.org/0000-0002-1487-5479)
- Lin Luo (ORCID: https://orcid.org/0000-0002-3152-7863)
- Yanmei Liu (ORCID: https://orcid.org/0000-0001-9380-2560)
- Yingjun Zhang (ORCID: https://orcid.org/0000-0002-6292-8045)
- Xue Wu (ORCID: https://orcid.org/0000-0002-0511-9436)
- Qingqing Wu (ORCID: https://orcid.org/0000-0003-4105-290X)
- Liang Xin
Institutions
- Shanghai Xuhui Central Hospital (CN)
- Shanghai Institute of Hematology (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.3389/fphar.2025.1500974
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00